發(fā)布時間：2018-12-11 06:42

【摘要】：目的觀察阿利吉侖治療中青年高血壓的臨床效果以及對患者腎素-血管緊張素-醛固酮系統(tǒng)(RAAS)的影響。方法將106例中青年高血壓患者隨機分為觀察組和對照組各53例,觀察組口服阿利吉侖,對照組口服依那普利。兩組均4周為1個療程,共觀察2個療程。治療前及治療后第8周行動脈血壓監(jiān)測,治療前及治療后第4、8周取血檢測血漿腎素活性(PRA)、血管緊張素Ⅱ(AngⅡ)、醛固酮(ALD),觀察治療期間降壓藥物不良反應(yīng),治療前及治療后半年行心臟彩色超聲檢查。結(jié)果觀察組收縮壓下降值、舒張壓下降值、脈壓下降值和收縮壓谷峰比值高于對照組,差異有統(tǒng)計學意義(P均0.05)。治療第4周,觀察組血漿PRA、AngⅡ、ALD水平低于治療前(P均0.05);治療第8周,兩組血漿PRA、AngⅡ、ALD水平均低于治療前,且觀察組低于對照組(P均0.05)。治療后半年時,觀察組舒張末期室間隔厚度、左心室內(nèi)徑、左心室后壁厚度及A/E小于對照組,左心室射血分數(shù)高于對照組,差異有統(tǒng)計學意義(P均0.05)。兩組藥物不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學意義。結(jié)論阿利吉侖調(diào)控中青年高血壓效果較好,能明顯阻斷RAAS活性,保護靶器官,且安全性良好。
[Abstract]:Objective to observe the clinical effect of alligilun in the treatment of young and middle-aged hypertension and its effect on (RAAS) of renin-angiotensin-aldosterone system. Methods 106 young and middle-aged patients with hypertension were randomly divided into observation group (53 cases) and control group (53 cases). The two groups were treated for 4 weeks and 2 courses were observed. Arterial blood pressure was monitored before and 8 weeks after treatment. Plasma renin active (PRA), angiotensin 鈪，

本文編號：2372080